BioArt reports on a Science study by Bowen Li's team, which used nonviral delivery of chemically modified tRNA to restore protein synthesis interrupted by premature stop codons. The source cites only the 2023 Nobel Prize to Karikó and Weissman for nucleoside modifications as background, noting that different RNAs require their own modification recipes, and provides no specific experimental data.
Why it matters: The source reports a nonviral strategy delivering chemically modified tRNA to restore prematurely terminated protein synthesis, useful for comparison with existing tRNA therapies.
A paper on the UniPert-G2CP framework, developed jointly by Tencent's AI for Life Sciences lab and Min Li's team at Central South University, has been accepted by Cell. It is the first AI virtual cell study from China published in the flagship journal Cell.
Why it matters: Its two-stage framework unifies genetic and chemical perturbations in a shared semantic space, offering a transferable path from molecular prediction to cell-level validation in AI drug discovery.
A Science paper shows that tumor-local PGE2 drives cancer-associated cachexia through the vagus nerve in LKB1 (STK11)-mutant lung adenocarcinoma, explaining why high-fat diets may backfire in this subtype. BioArtMED reviews the study and notes that circulating inflammatory factors such as IL-6 and GDF15 were previously seen as the main cachexia drivers, but they cannot explain the differing responses of specific mutation subtypes to dietary intervention.
Why it matters: The review explains the Science paper's mechanism of tumor-local PGE2 driving cachexia via the vagus nerve, giving an experimental answer to why high-fat diets may worsen outcomes in LKB1-mutant lung adenocarcinoma.
A Nature study reports a modular ADC platform based on click chemistry. In preclinical models co-expressing HER2 and EGFR, it showed stronger antitumor activity than standard ADC monotherapy or antibody combinations. The platform works against tumors with low, ultralow, negative, or heterogeneous HER2 expression, and overcomes limitations of conventional HER2-ADC resistance models.
Why it matters: Click chemistry ADC platform bypasses dependence on high single-target expression in preclinical models, offering a modular approach for HER2-low and heterogeneous tumors.
Moderna and Merck's jointly developed mRNA cancer vaccine intismeran autogene reduced the risk of recurrence or spread in patients whose melanoma had been surgically removed, in a trial of 1,137 volunteers. After the top-line results, some investors and longtime skeptics of mRNA technology still called for waiting for the full data. The article recounts an off-site Moderna leadership meeting in March 2023, tracing the vaccine's development from concept to its pivotal readout.
Why it matters: The article traces the mRNA cancer vaccine from widespread doubt to positive readout through Moderna executives' recollections, useful as background for similar programs.
Stanford University published a study in Science using two genome language models, Evo 1 and Evo 2, to design viral genomes. Sixteen phages were synthesized in the lab that can infect, replicate in, and kill bacteria. The paper describes the two models simply as DNA versions of large language models.
Moderna and Merck have announced positive topline results from the late-stage INTerpath-001 study of the personalized neoantigen therapy intismeran autogene (V940/mRNA-4157) combined with KEYTRUDA as adjuvant treatment after surgery for high-risk melanoma. The companies described it as the first positive late-stage readout for a personalized neoantigen therapy and for mRNA cancer treatment.
Why it matters: Brief lists the drug, trial and indication for the first positive late-stage neoantigen readout, and uses it to discuss domestic pipelines.
A rapidly spreading haplotype on chromosome 7 of Plasmodium falciparum, carrying mutations and deletions in the px1 gene, is strongly associated with reduced parasite susceptibility to the first-line antimalarials lumefantrine and dihydroartemisinin in Uganda. The finding identifies px1 as a linked locus in declining drug susceptibility and adds a genetic marker for tracking emerging resistance.
Merck and the Walter and Eliza Hall Institute report a chemovaccination strategy in Science: low-dose malaria parasite infection combined with dual inhibitors of plasmepsin IX and X kills the parasite at the late liver stage, allowing it to replicate fully in liver cells, produce abundant antigen, and generate durable sterile immunity.
Why it matters: The paper describes using dual plasmepsin IX/X inhibitors to convert liver-stage malaria infection into durable sterile immunity, a chemovaccination route for parasitic diseases lacking effective vaccines.
A team led by Alexander Marson at the Gladstone Institutes in the United States published a study titled "In vivo genome-wide CRISPR screens of human T cells in solid tumours" online in Nature. A Chinese scholar is first author and corresponding author.
Why it matters: Moves genome-wide CRISPR screening from culture dishes to living tumours, providing a directly comparable method for finding targets that enhance CAR-T in solid tumours.
AstraZeneca has discontinued the global Phase 3 eVOLVE-Lung02 trial of the PD-1/CTLA-4 bispecific antibody volrustomig plus chemotherapy versus pembrolizumab plus chemotherapy in PD-L1 <50% lung cancer. The independent data monitoring committee judged the study unlikely to meet either the OS or PFS primary endpoint. The author notes this follows the failure of KEYNOTE-598 as a second setback for the CTLA-4 pathway in this setting.
Hernández-Verdin et al. show that cancer-derived gamma-aminobutyric acid (GABA) acts as an immunosuppressant factor that renders tertiary lymphoid structures (TLSs) dysfunctional and drives resistance to immunotherapy in some tumors. Targeting GABA together with immunotherapy reshaped the tumor and TLS microenvironment and improved therapeutic efficacy. The work points to GABA as a candidate target for overcoming TLS-associated immunotherapy resistance.
A study published in Cell used CRISPR screening to search for new targets that could reverse age-related failure of antitumor immunity. The article reviews mechanisms by which T cell antitumor immunity declines with age, noting that older cancer patients have lower response rates to immune checkpoint inhibitors and are more prone to immune-related adverse events.
Why it matters: Age-related decline in T cell antitumor immunity underlies low ICB response rates in older patients, motivating the Cell study's CRISPR screen.
On August 13, 2026, a team led by Nicolas Thomä and Bruno Correia at EPFL (Swiss Federal Institute of Technology Lausanne) published a study titled "Proteome-wide identification of the druggable CRBN interactome" in Nature Biotechnology.
Why it matters: Reports AI mapping of the proteome-wide CRBN molecular glue binding landscape, shifting from degradation to a binding view for target discovery.
On August 12, Nature published a study from a University of California, San Francisco team. Using what is described as the world's first in vivo genome-wide CRISPR screen in human T cells, the researchers identified P2RY8-GNAS as a new target that helps CAR-T cells infiltrate and fight solid tumors more effectively.
Why it matters: In vivo genome-wide CRISPR screening in human T cells identified P2RY8-GNAS, a candidate target and screening paradigm for solid tumor CAR-T amenable to comparison with existing approaches.
A study published in Cell reports a bivalent molecular glue that bridges p300/CBP with BCL6, activating a cell death program in lymphoma cells. Using chemically induced proximity (CIP), the work targets oncogenic transcription networks that p300/CBP supports in malignant tumors by maintaining enhancer and super-enhancer activity.
Why it matters: Bridging p300/CBP with BCL6 via chemically induced proximity offers another approach to targeting enhancer-driven oncogenic transcription networks.
A Cell paper, reported by BioArt, delineates the complete mechanism of the bacterial DRT3 immune system. DRT3 contains both Class 1 and Class 2 reverse transcriptase components and synthesizes double-stranded DNA using both RNA and protein as templates to defend against phage, with protein-templated reverse transcription reported for the first time. The paper was submitted May 2, accepted July 8, and published online July 28.
Why it matters: The paper gives the mechanism by which DRT3 synthesizes double-stranded DNA from RNA and protein templates, allowing readers to compare it with known reverse-transcriptase immune systems.
Science reports the first AI-designed bacteriophage virus, capable of surviving, infecting host cells, and combating antibiotic resistance. The original article notes that previous AI designs were mostly limited to single genes or proteins, while this work achieves genome-scale design, providing a blueprint for building diverse synthetic phages and practical biological systems.
Why it matters: Notes the key advance from single-gene design to whole-genome-scale phage design, useful for assessing the boundaries of AI synthetic biology.
AbbVie has registered a Phase III trial (NCT07756645) on ClinicalTrials.gov comparing ABBV-1480 plus chemotherapy against pembrolizumab plus chemotherapy as first-line treatment in 940 patients with locally advanced or metastatic non-small cell lung cancer. ABBV-1480 (RC148) is a PD-1/VEGF bispecific antibody from RemeGen that AbbVie licensed in January for ex-Greater China rights with $650 million upfront and a $5.5 billion total deal value. The trial is expected to start in September 2026 and finish in December 2029, with PFS and OS as primary endpoints.
A Stanford University team reports in Nature that during aging, large numbers of bone marrow-derived immune cells enter the brain and convert into microglia. The finding challenges the prior view that microglia arise from embryonic settlers in the brain, self-renew throughout life, and barely interact with the peripheral immune system.
Why it matters: Stanford Nature paper shows bone marrow-derived immune cells can replenish brain microglia during aging, adding evidence on microglial origin and renewal.
